Sarepta Therapeutics (SRPT) Short-term Investments (2013 - 2026)

Sarepta Therapeutics' Short-term Investments history runs 14 years deep, the most recent figure standing at $188.7 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 33.05% year-over-year to $188.7 million; the TTM figure through Mar 2026 stood at $188.7 million (down 33.05% YoY), while the FY2025 annual figure was $138.4 million, down 45.04% from the prior year.
• Short-term Investments was $188.7 million for Q1 2026 at Sarepta Therapeutics, up from $138.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $1.2 billion in Q4 2023 to a low of $138.4 million in Q4 2025.
• Historically, Short-term Investments has averaged $752.0 million across 5 years, with a median of $1.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Short-term Investments soared 3431.51% in 2022, then tumbled 79.82% in 2024.
• A 5-year view of Short-term Investments shows it stood at $1.0 billion in 2022, then rose by 22.02% to $1.2 billion in 2023, then sank by 79.82% to $251.8 million in 2024, then sank by 45.04% to $138.4 million in 2025, then surged by 36.4% to $188.7 million in 2026.
• The last three Short-term Investments figures came in at $188.7 million (Q1 2026), $138.4 million (Q4 2025), and $237.9 million (Q3 2025), per Business Quant data.